Niki BioSolutions, Inc. (NIKI) Financials
A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Sep 25, 2026; every other figure is from the SEC filings on this page. Not financial advice.
Newest figures come from the 10-K for FY2025, filed May 11, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the NIKI SEC filings page.
This page shows Niki BioSolutions, Inc. (NIKI) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 8 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Financial Health Signals
Niki BioSolutions, Inc. does not currently provide enough eligible data for a peer-relative financial health score, so none is published. The signals and metrics below are current.
Niki BioSolutions, Inc. passes 2 of 5 computable financial strength tests (4 of the nine could not be computed from available data). 1 of 4 profitability signals pass, all 1 leverage/liquidity signals pass.
Niki BioSolutions, Inc. reported a net loss of $1.4M while operations used $1.8M of cash. With neither figure positive, the ratio between the two carries no quality signal.
Key Financial Metrics
Earnings & Revenue
Niki BioSolutions, Inc. earned -$0.04 per diluted share (EPS) in Q4 2025. This represents an increase of 75.0% from the same quarter a year earlier.
Not reported for Q4 2025.
Not reported for Q4 2025.
Not reported for Q4 2025.
Cash & Balance Sheet
Niki BioSolutions, Inc. held $3.5M in cash as of Q4 2025; long-term debt is not reported for that period.
Not reported for Q4 2025.
Not reported for Q4 2025.
Margins & Returns
None of these metrics is reported for Q4 2025.
Capital Allocation
None of these metrics is reported for Q4 2025.
NIKI Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
Not reported in any period shown, so not listed: Revenue, Cost of Revenue, Gross Profit, R&D Expenses, SG&A Expenses, Operating Income, EBITDA, Interest Expense, Income Tax, Net Income, Diluted Shares (Avg).
NIKI Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q4'2510-K | Q3'2510-Q | Q2'2510-K | Q4'2410-K | Q3'2410-Q | Q2'2410-Q | Q4'2310-K | Q2'2310-Q |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $18.7M+15.9% | $17.6M | $18.1M+2.3% | $16.1M-21.9% | N/A | $17.7M+22.8% | $20.6M-1.1% | $14.4M-40.0% |
| Current Assets | $3.6M+274.4% | $2.5M | $3.0M+95.9% | $960K-61.2% | N/A | $1.5M-19.2% | $2.5M-65.0% | $1.9M-79.6% |
| Cash & Equivalents | $3.5M+295.0% | $2.3M+201.2% | $2.8M+252.1% | $874K-56.4% | $755K | $783K+130.1% | $2.0M-60.0% | $340K-91.6% |
| Short-Term Investments | $0 | $0 | $0 | $0 | $0 | $0 | $0-100.0% | $0 |
| Accounts Receivable | N/A | N/A | N/A | N/A | N/A | $22K-67.2% | $48K-72.6% | $66K-7.5% |
| Long-Term Investments | $15.1M0.0% | $15.1M | $15.1M-6.2% | $15.1M-6.2% | $0 | $16.1M+65.2% | $16.1M+65.2% | $9.7M+12523.0% |
| Total Liabilities | -$4.4M+11.6% | -$5.0M | -$5.0M-1.6% | -$5.0M-19.0% | N/A | -$5.0M+33.4% | -$4.2M-181.6% | -$7.4M-641.8% |
| Current Liabilities | $4.6M+5.9% | $4.4M | $1.0M-23.5% | $4.3M+106.7% | N/A | $1.3M-8.2% | $2.1M | $1.4M |
| Non-Current Liabilities | -$9.0M+3.5% | -$9.4M | -$6.0M+3.7% | -$9.3M-48.2% | N/A | -$6.3M+29.3% | -$6.3M | -$8.9M |
| Total Equity | $23.1M+9.4% | $22.5M+80.0% | $23.1M+2.1% | $21.1M-14.9% | $12.5M | $22.7M+3.7% | $24.8M+58.1% | $21.8M-3.5% |
| Retained Earnings | -$73.8M-1.9% | -$73.5M | -$72.9M-2.9% | -$72.4M-6.3% | N/A | -$70.8M0.0% | -$68.2M-4.3% | -$70.8M-23.3% |
Not reported in any period shown, so not listed: Inventory, Goodwill, Long-Term Debt.
NIKI Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
Not reported in any period shown, so not listed: Stock-Based Compensation, Capital Expenditures, Free Cash Flow, Dividends Paid, Share Buybacks.
NIKI Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
Not reported in any period shown, so not listed: Gross Margin, Operating Margin, Net Margin, Return on Equity, Return on Assets, Debt-to-Equity, Asset Turnover, FCF Margin.
Note: The current ratio is below 1.0 (0.78), indicating current liabilities exceed current assets, which may suggest potential short-term liquidity concerns.
Where Niki BioSolutions, Inc. Ranks
Frequently Asked Questions
Is Niki BioSolutions, Inc. profitable?
No, Niki BioSolutions, Inc. (NIKI) reported a net income of -$1.4M in fiscal year 2025.
What is Niki BioSolutions, Inc.'s return on equity (ROE)?
Niki BioSolutions, Inc. (NIKI) has a return on equity of -5.9% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.
What is Niki BioSolutions, Inc.'s operating cash flow?
Niki BioSolutions, Inc. (NIKI) recorded an outflow of $1.8M in operating cash flow during fiscal year 2025, representing cash used by core business activities.
What are Niki BioSolutions, Inc.'s total assets?
Niki BioSolutions, Inc. (NIKI) had $18.7M in total assets as of fiscal year 2025, including both current and long-term assets.
How much does Niki BioSolutions, Inc. spend on research and development?
Niki BioSolutions, Inc. (NIKI) invested $353K in research and development during fiscal year 2025.
What is Niki BioSolutions, Inc.'s current ratio?
Niki BioSolutions, Inc. (NIKI) had a current ratio of 0.78 as of fiscal year 2025, which is below 1.0, which may suggest potential liquidity concerns.
What is Niki BioSolutions, Inc.'s return on assets (ROA)?
Niki BioSolutions, Inc. (NIKI) had a return on assets of -7.3% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
What is Niki BioSolutions, Inc.'s P/E ratio?
Niki BioSolutions, Inc. (NIKI) has no price-to-earnings ratio at the moment: net loss, so no earnings multiple (FY2025). The market capitalization is $4.0M as of Sep 25, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
What is Niki BioSolutions, Inc.'s price-to-sales ratio?
Niki BioSolutions, Inc. (NIKI) has no price-to-sales ratio at the moment: no revenue reported. The market capitalization is $4.0M as of Sep 25, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
What is Niki BioSolutions, Inc.'s Piotroski F-Score?
Niki BioSolutions, Inc. (NIKI) has a Piotroski F-Score of 2 out of 5 computable signals; 4 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Niki BioSolutions, Inc.'s earnings high quality?
Niki BioSolutions, Inc. (NIKI) reported a net loss of $1.4M while operations used $1.8M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.